Fisetin vs Humanin
A side-by-side research comparison of Fisetin and Humanin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Fisetin | Humanin |
|---|---|---|
| Full name | Fisetin (Senolytic Flavonoid) | Humanin (HN) Mitochondrial-Derived Peptide |
| Category | Anti-Aging | Anti-Aging |
| Status | Dietary compound (research ongoing) | Research compound |
| Mechanism | Acts as a senolytic by tipping senescent cells toward apoptosis (programmed death) while sparing healthy cells. Also has antioxidant and anti-inflammatory activity. | Binds IGFBP-3, BAX, and trimeric receptor (CNTFR/WSX-1/gp130) to activate STAT3. Inhibits mitochondrial apoptosis and provides neuroprotection. |
| Molecular weight | 286.24 Da | 2,687 Da |
| Half-life | Short; poor baseline absorption (often taken with fat) | 4-6 hours |
| Bioavailability | Low oral; improved with lipids/liposomal forms | Moderate (SubQ) |
| Typical dose | ~20 mg/kg on hit days (protocol-dependent) | 1-5 mg |
| Frequency | Intermittent "hit and run" courses | 3-5x per week |
| Route | Oral | Subcutaneous |
Fisetin reported benefits
- Senolytic (clears senescent cells)
- Antioxidant and anti-inflammatory
- Studied for healthspan extension
- Neuroprotective signals in research
Humanin reported benefits
- Neuroprotection against amyloid-beta
- Anti-apoptotic
- Improved insulin sensitivity
- Cardioprotection
- Cellular stress resistance
Related comparisons
Research and educational reference only. Not medical advice.